Introduction
Cyclin D1 is a major regulator of the cell cycle transition from G1 phase to S phase. It forms a complex with cyclindependent kinases 4 and 6 and also phosphorylates the retinoblastoma protein (Sherr, 1996) . Cyclin D1 is encoded by the cyclin D1 gene (CCND1) located on chromosome 11q13 (Hunter and Pines, 1994) . Cyclin D1 overexpression and CCND1 amplification have been demonstrated in a variety of cancers including breast, head and neck, esophageal, colorectal, genitourinary, lung, and skin cancers and hepatocellular carcinoma (Donnellan and Chetty, 1998) . Betticher et al. (1995) originally identified a CCND1 polymorphism (G to A) at codon 242, the boundary of exon 4 and intron 4. The A allele was more likely not to splice at the normal junction, leaving the coding sequence reading into intron 4. This variant (transcript b) lacks the carboxy-terminal region encoded by exon 5, which is responsible for rapid turnover. Therefore, this protein may have a longer half-life than the G allele (transcript a). A recent study by Kong et al. (2000) demonstrated that in families with nonpolyposis colorectal cancer the age of onset of colorectal cancer varied according to variation at this polymorphic site.
Hepatoblastoma is an embryonal tumor of the liver, which occurs in young infants and children (Bulterys et al., 1999) . It is the only malignant tumor of the gastrointestinal system which occurs with significant frequency in children. Hepatoblastoma is associated with overgrowth syndromes in childhood including the Beckwith-Wiedemann syndrome (DeBaun and Tucker, 1998) . Hepatoblastoma shares some similar molecular features with colorectal cancers in adults, including an association with alteration of the APC gene and mutation of the b-catenin gene (Kurahashi et al., 1995; Oda et al., 1996; Koch et al., 1999; Jeng et al., 2000; Takayasu et al., 2001) . Shtutman et al. (1999) demonstrated that b-catenin with transcription factors of the lymphoid-enhancing factor (LEF) family activates the CCND1 promoter, resulting in the elevation of CCND1 expression and protein level. To further investigate the role of the b-catenin/LEF pathway in hepatoblastomas, we studied the effect of CCND1 polymorphism on the risk of this childhood malignancy.
Methods
We collected peripheral blood from hepatoblastoma patients who were newly diagnosed at the Children's Medical Center of Dallas and other cooperating institutions, including institutions participating in the Pediatric Oncology Group Hepatoblastoma Biology Study. Informed consent for genetic studies was obtained from parents. We recorded data including age at diagnosis, gender, and ethnicity. Blood samples from healthy individuals with no history of cancer were matched by ethnicity to patients and used as normal controls. Genomic DNA from peripheral blood was used to analyse the CCND1 polymorphic site (G vs A) at codon 242 in exon 4. PCR amplification was carried out using primers and conditions as described by Kong et al. (2000) . Single-strand conformation polymorphism (SSCP) analysis was performed according to the method of Orita et al. (1989) for purposes of distinguishing the CCND1 exon 4 genotypes. The genotype patterns were demonstrated as shown in Figure 1 .
The Kruskal-Wallis (KW) test was used to assess the association between genotype and age at diagnosis. Contingency table analyses using exact methods were used to compare genotype with case-control status. The magnitude of association was estimated as the odds ratio (OR) with a 95% confidence interval. Analyses were performed using Statistical Analysis System (SAS version 8, SAS Institute, Cary, NC, USA) and StatXact 5 (Cytel Corp., Cambridge, MA, USA).
Results
We identified the genotype of the CCND1 polymorphism in 84 hepatoblastoma patients. The median age at diagnosis was 18 months (range 1-126 months). Male to female ratio was 1.6 : 1. The study population consisted of 57 Caucasians with a median age of 17 months (range 1-126 months), seven African Americans with a median age of 27 months (range 9-44 months), and 15 Hispanics with a median age of 17 months (range 2-23 months). There were also three patients of Asian background and four of uncertain ethnic background.
We examined the relationship of age of onset and genotype and found a correlation between the median age of onset and genotype. As shown in Table 1 , there were 28 patients with G/G genotype, 35 with G/A genotype, and 21 with A/A genotype. The median age of patients with the G/G genotype was 22 months (range 1-126 months). The median age at diagnosis of patients with the G/A genotype was 17 months (range 2-57 months), and the median age for the A/A genotype was 11 months (range 2-47 months) (See Figure 2) . There was a nonstatistically significant trend in genotype being associated with age at diagnosis (P ¼ 0.101, KW test) for all the three groups. However, a two-sample t-test with unequal variance comparing the A/A to the G/G group was highly significant (Po0.001). We also assessed the association between individual allele frequencies and age. There was a nonsignificant trend with a lower mean age (7s.d.) for the A allele, 17.5713.1 years, compared with the G allele, 23.7722.7 years (P ¼ 0.08, KW test).
The genotype distribution for cases and controls was assessed and is shown in Table 2 . There was no crude association between genotype distribution and cases and controls. When stratified by race, there was effect measure modification (Po0.001, homogeneity test); therefore, it was not possible to estimate a common OR across the race groups. The overall frequency of the AA genotype was 22.9% in cases and 20.1% in normal controls in Caucasians (OR ¼ 1.13, CI ¼ 0.43-2.96). The number of African-American cases was small overall; however, the AA genotype was prevalent in one case (17%) compared to 6% of normal controls. Likewise, 
Discussion
It has been demonstrated that the b-catenin/LEF pathway is involved in the tumorigenesis of hepatoblastomas (Koch et al., 1999; Jeng et al., 2000; Takayasu et al., 2001) . CCND1 has been shown to be one of the target genes of this pathway (Shtutman et al., 1999) . In this study, we demonstrate that the A/A genotype of CCND1 polymorphism is associated with an earlier age of onset of hepatoblastomas compared to G/G or G/A genotypes. This effect on the age of tumor onset by the CCND1 genotype was similar to that recently reported by Kong et al. (2000) in their study of patients with hereditary nonpolyposis colon cancer (HNPCC). Kong et al. found that the median age of A/A genotype patients was 11 years younger than those with the G/G genotype. The explanation of this effect is unclear.
Patients with HNPCC have an inherent tendency to develop and retain mutations because of a constitutional defect in DNA repair. Since the A allele produces transcript b, which might extend the longer half-life of cyclin D1, this might allow the damaged cells to pass through the cell cycle, and then progress to cancer. In contrast, Sawa et al. (1998) showed that overexpression of transcript b reduced the proportion of cells in the proliferation pool (i.e., in G1, S, or G2/M) in vitro, and that a high level of transcript a inhibited cells from entering and completing the S phase by increasing p21. However, these data could not be confirmed in a study of this polymorphism in colorectal cancer (McKay et al., 2000) . We found no overall difference in genotype frequency between cases and normal controls in our populations. Our results support previous data showing that there was no difference of genotype frequencies in patients with NSCLC, colorectal cancer, and head and neck cancer compared to normal controls (Betticher et al., 1995; Matthias et al., 1998; McKay et al., 2000) . However, in contrast, Kong et al. (2001) recently demonstrated that the A/A genotype increased the risk of nonsyndromic colorectal adenocarcinoma. It thus appears that this polymorphism may act by either influencing cancer susceptibility or by modulating the age of cancer onset.
Our data suggest that the allele frequency is different among ethnicities. The A allele frequency was reported to be 42% in Europeans (Betticher et al., 1995) and 47% in the Japanese (Hollander and Wolfe, 1999) . Here, we demonstrate the A allele frequency to be 43% in Caucasians, 21% in African Americans, and 41% in Hispanics. Larger sample sizes of patients will be needed, however, to correlate the ethnic differences in population frequencies with disease characteristics.
In summary, we suggest that the G/A exon 4 polymorphism in CCND1 is correlated with the age of onset of hepatoblastomas. The A/A genotype is associated with an earlier age of onset compared to the G/A or G/G genotype. This result is similar to that observed previously in HNPCC. Further studies of cyclin D1 and its relationship to APC, b-catenin as part of the Wnt signaling pathway in this pediatric tumor type as well as in colorectal cancers in adults should be done to explore the genetic mechanism of tumorigenesis.
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